Literature DB >> 27077479

Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.

Megha H Talati1, Evan L Brittain2, Joshua P Fessel1,3, Niki Penner1, James Atkinson4, Mitch Funke1, Carrie Grueter5, W Gray Jerome4,6, Michael Freeman7, John H Newman1, James West1, Anna R Hemnes1.   

Abstract

RATIONALE: In heritable pulmonary arterial hypertension with germline mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, right ventricle (RV) dysfunction is associated with RV lipotoxicity; however, the underlying mechanism for lipid accumulation is not known.
OBJECTIVES: We hypothesized that lipid accumulation in cardiomyocytes with BMPR2 mutation occurs owing to alterations in lipid transport and impaired fatty acid oxidation (FAO), which is exacerbated by a high-lipid (Western) diet (WD).
METHODS: We used a transgenic mouse model of pulmonary arterial hypertension with mutant BMPR2 and generated a cardiomyocyte cell line with BMPR2 mutation. Electron microscopy and metabolomic analysis were performed on mouse RVs.
MEASUREMENTS AND MAIN RESULTS: By metabolomics analysis, we found an increase in long-chain fatty acids in BMPR2 mutant mouse RVs compared with controls, which correlated with cardiac index. BMPR2-mutant cardiomyocytes had increased lipid compared with controls. Direct measurement of FAO in the WD-fed BMPR2-mutant RV showed impaired palmitate-linked oxygen consumption, and metabolomics analysis showed reduced indices of FAO. Using both mutant BMPR2 mouse RVs and cardiomyocytes, we found an increase in the uptake of (14)C-palmitate and fatty acid transporter CD36 that was further exacerbated by WD.
CONCLUSIONS: Taken together, our data suggest that impaired FAO and increased expression of the lipid transporter CD36 are key mechanisms underlying lipid deposition in the BMPR2-mutant RV, which are exacerbated in the presence of dietary lipids. These findings suggest important features leading to RV lipotoxicity in pulmonary arterial hypertension and may point to novel areas of therapeutic intervention.

Entities:  

Keywords:  fatty acid oxidation; fatty acid transporter (CD36); lipotoxic cardiomyopathy; pulmonary arterial hypertension; right ventricular lipotoxicity

Mesh:

Substances:

Year:  2016        PMID: 27077479      PMCID: PMC5027228          DOI: 10.1164/rccm.201507-1444OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  53 in total

1.  Detection of impaired fatty acid metabolism in right ventricular hypertrophy: assessment by I-123 beta-methyl iodophenyl pentadecanoic acid (BMIPP) myocardial single-photon emission computed tomography.

Authors:  Y Kim; H Goto; K Kobayashi; Y Sawada; Y Miyake; G Fujiwara; H Chiba; T Okada; T Nishimura
Journal:  Ann Nucl Med       Date:  1997-08       Impact factor: 2.668

2.  L-type calcium channels, potassium channels, and novel nonspecific cation channels in a clonal muscle cell line derived from embryonic rat ventricle.

Authors:  K R Sipido; E Marban
Journal:  Circ Res       Date:  1991-12       Impact factor: 17.367

3.  Properties of a clonal muscle cell line from rat heart.

Authors:  B W Kimes; B L Brandt
Journal:  Exp Cell Res       Date:  1976-03-15       Impact factor: 3.905

Review 4.  Heart sphingolipids in health and disease.

Authors:  Marcin Baranowski; Jan Górski
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

5.  Succinimidyl oleate, established inhibitor of CD36/FAT translocase inhibits complex III of mitochondrial respiratory chain.

Authors:  Zdenek Drahota; Marek Vrbacký; Hana Nůsková; Ludmila Kazdová; Václav Zídek; Vladimír Landa; Michal Pravenec; Josef Houstek
Journal:  Biochem Biophys Res Commun       Date:  2009-12-16       Impact factor: 3.575

6.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.

Authors:  Benjamin Sztrymf; Florence Coulet; Barbara Girerd; Azzedine Yaici; Xavier Jais; Olivier Sitbon; David Montani; Rogério Souza; Gerald Simonneau; Florent Soubrier; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

7.  Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that of GLUT4.

Authors:  Masja M van Oort; Jan M van Doorn; Arend Bonen; Jan F C Glatz; Dick J van der Horst; Kees W Rodenburg; Joost J F P Luiken
Journal:  Biochim Biophys Acta       Date:  2007-12-15

8.  Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids.

Authors:  Hiroshi Irie; Irvin B Krukenkamp; Joep F F Brinkmann; Glenn R Gaudette; Adam E Saltman; William Jou; Jan F C Glatz; Nada A Abumrad; Azeddine Ibrahimi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

9.  CD36 deficiency rescues lipotoxic cardiomyopathy.

Authors:  John Yang; Nandakumar Sambandam; Xianlin Han; Richard W Gross; Michael Courtois; Attila Kovacs; Maria Febbraio; Brian N Finck; Daniel P Kelly
Journal:  Circ Res       Date:  2007-03-15       Impact factor: 17.367

10.  Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery.

Authors:  Jeevan Nagendran; Thomas Pulinilkunnil; Petra C Kienesberger; Miranda M Sung; David Fung; Maria Febbraio; Jason R B Dyck
Journal:  J Mol Cell Cardiol       Date:  2013-08-12       Impact factor: 5.000

View more
  43 in total

1.  Fatty Acid Metabolism, Bone Morphogenetic Protein Receptor Type 2, and the Right Ventricle.

Authors:  Brian B Graham; Jeffrey C Robinson; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

2.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 3.  Endothelial Cell Metabolism.

Authors:  Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

4.  BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes.

Authors:  Anna R Hemnes; Joshua P Fessel; Xinping Chen; Shijun Zhu; Niki L Fortune; Christopher Jetter; Michael Freeman; John H Newman; James D West; Megha H Talati
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-12-18       Impact factor: 5.464

5.  17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.

Authors:  Andrea L Frump; Marjorie Albrecht; Bakhtiyor Yakubov; Sandra Breuils-Bonnet; Valérie Nadeau; Eve Tremblay; Francois Potus; Junichi Omura; Todd Cook; Amanda Fisher; Brooke Rodriguez; R Dale Brown; Kurt R Stenmark; C Dustin Rubinstein; Kathy Krentz; Diana M Tabima; Rongbo Li; Xin Sun; Naomi C Chesler; Steeve Provencher; Sebastien Bonnet; Tim Lahm
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 6.  Beyond BMI: Obesity and Lung Disease.

Authors:  Ubong Peters; Benjamin T Suratt; Jason H T Bates; Anne E Dixon
Journal:  Chest       Date:  2017-07-17       Impact factor: 9.410

Review 7.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

Review 8.  Energy metabolism: A newly emerging target of BMP signaling in bone homeostasis.

Authors:  Jingwen Yang; Hiroki Ueharu; Yuji Mishina
Journal:  Bone       Date:  2020-06-05       Impact factor: 4.398

Review 9.  Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.

Authors:  Bradley A Maron; Jane A Leopold; Anna R Hemnes
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

10.  Improving Right Ventricular Function by Increasing BMP Signaling with FK506.

Authors:  Mario Boehm; Xuefei Tian; Md Khadem Ali; Yuqiang Mao; Kenzo Ichimura; Mingming Zhao; Kazuya Kuramoto; Svenja Dannewitz Prosseda; Giovanni Fajardo; Melanie J Dufva; Xulei Qin; Vitaly O Kheyfets; Daniel Bernstein; Sushma Reddy; Ross J Metzger; Roham T Zamanian; Francois Haddad; Edda Spiekerkoetter
Journal:  Am J Respir Cell Mol Biol       Date:  2021-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.